Ethics and Nanopharmacy: Value Sensitive Design of New Drugs

Although applications are being developed and have reached the market, nanopharmacy to date is generally still conceived as an emerging technology. Its concept is ill-defined. Nanopharmacy can also be construed as a converging technology, which combines features of multiple technologies, ranging from nanotechnology to medicine and ICT. It is still debated whether its features give rise to new ethical issues or that issues associated with nanopharma are merely an extension of existing issues in the underlying fields. We argue here that, regardless of the alleged newness of the ethical issues involved, developments occasioned by technological advances affect the roles played by stakeholders in the field of nanopharmacy to such an extent that this calls for a different approach to responsible innovation in this field. Specific features associated with nanopharmacy itself and features introduced to the associated converging technologies- bring about a shift in the roles of stakeholders that call for a different approach to responsibility. We suggest that Value Sensitive Design is a suitable framework to involve stakeholders in addressing moral issues responsibly at an early stage of development of new nanopharmaceuticals

Quality criteria and structure of silica gel column packing material

Silica gel and derivatised forms of silica gel are by far the most commonly used column packing materials in high-performance liquid chromatography. Quality criteria of silica gel for chromatography therefore merit attention. Most of them are discussed, and it is suggested that the apparent density is an important one

Vuurwapengeweld in België - Op zoek naar een completer beeld

info:eu-repo/semantics/publishe

Measuring activity patterns using actigraphy in multiple sclerosis

Huetz de Lemps Alain. Montaggioni, L., et Nativel, P. La Réunion-Ile Maurice. 1988. In: Cahiers d'outre-mer. N° 166 - 42e année, Avril-juin 1989. p. 219